呼吸系統的共同研究·授權契約(2016年～2025年)

本報告提供全球生物醫藥品產業調查分析，提供2016年～2025年的呼吸系統的共同研究·授權契約425件相關，契約條件等詳細資訊。

目錄

摘要整理

第1章 簡介

第2章 呼吸系統契約趨勢

• 簡介
• 過去數年的呼吸系統合作夥伴契約
• 呼吸系統合作夥伴契約:各類型契約
• 呼吸系統合作夥伴契約:各產品部門
• 呼吸系統合作夥伴契約:各開發階段
• 呼吸系統合作夥伴契約:各技術類型
• 呼吸系統合作夥伴契約:各適應症

第3章 呼吸系統合作夥伴契約相關財務的契約條件

• 簡介
• 呼吸系統合作夥伴契約相關公開的財務條件
• 呼吸系統合作夥伴契約的標題金額
• 呼吸系統契約的預付款
• 呼吸系統契約的階段性付款
• 呼吸系統的權利金費率

第4章 主要呼吸系統契約與談判者

• 簡介
• 在呼吸系統合作夥伴契約中最活躍
• 呼吸系統領域的最活躍的談判者的清單
• 前幾名的呼吸系統契約(金額)

第5章 呼吸系統契約文件名錄

• 簡介
• 合同可取得的呼吸系統合作夥伴契約

第6章 按呼吸系統契約:治療標的

• 簡介
• 契約:呼吸系統治療標的
• 契約名錄
• 契約名錄 - 呼吸系統契約:各企業(A～Z)(2016年～2025年)
• 契約名錄 - 呼吸系統契約:各技術類型(2016年～2025年)
• 契約類型定義
• 關於Bioharma Research Ltd
• Current Partnering
• Current Agreements
• Current Partnering的近幾年報告的標題

Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 425 respiratory deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of respiratory dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in respiratory dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the respiratory field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in respiratory dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of respiratory deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of respiratory deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in respiratory deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Respiratory Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse respiratory collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Respiratory Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of respiratory trends and structure of deals entered into by leading biopharma companies worldwide.

Respiratory Collaboration and Licensing Deals includes:

• Trends in respiratory dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of respiratory deal records covering pharmaceutical and biotechnology
• The leading respiratory deals by value
• Most active respiratory licensing dealmakers

In Respiratory Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Respiratory Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in respiratory dealmaking

• 2.1. Introduction
• 2.2. Respiratory partnering over the years
• 2.3. Respiratory partnering by deal type
• 2.4. Respiratory partnering by industry sector
• 2.5. Respiratory partnering by stage of development
• 2.6. Respiratory partnering by technology type
• 2.7. Respiratory partnering by therapeutic indication

Chapter 3 - Financial deal terms for respiratory partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for respiratory partnering
• 3.3. Respiratory partnering headline values
• 3.4. Respiratory deal upfront payments
• 3.5. Respiratory deal milestone payments
• 3.6. Respiratory royalty rates

Chapter 4 - Leading respiratory deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in respiratory partnering
• 4.3. List of most active dealmakers in respiratory
• 4.4. Top respiratory deals by value

Chapter 5 - Respiratory contract document directory

• 5.1. Introduction
• 5.2. Respiratory partnering deals where contract document available

Chapter 6 - Respiratory dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by respiratory therapeutic target
• Deal directory
• Deal directory - Respiratory deals by company A-Z 2016 to 2025
• Deal directory - Respiratory deals by technology type 2016 to 2025
• Deal type definitions
• About Bioharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Respiratory partnering since 2016
• Figure 2: Respiratory partnering by deal type since 2016
• Figure 3: Respiratory partnering by industry sector since 2016
• Figure 4: Respiratory partnering by stage of development since 2016
• Figure 5: Respiratory partnering by technology type since 2016
• Figure 6: Respiratory partnering by indication since 2016
• Figure 7: Respiratory deals with a headline value
• Figure 8: Respiratory deals with upfront payment values
• Figure 9: Respiratory deals with milestone payment
• Figure 10: Respiratory deals with royalty rates
• Figure 11: Active respiratory dealmaking activity since 2016
• Figure 12: Top respiratory deals by value since 2016